mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
16 Apr 2021
16 Apr 2021
Historique:
received:
12
12
2020
accepted:
07
03
2021
entrez:
17
4
2021
pubmed:
18
4
2021
medline:
18
4
2021
Statut:
epublish
Résumé
mRNA technologies have recently proven clinical efficacy against coronavirus disease 2019 and are among the most promising technologies to address the current pandemic. Here, we show preclinical data for our clinical candidate CVnCoV, a lipid nanoparticle-encapsulated mRNA vaccine that encodes full-length, pre-fusion stabilised severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. In contrast to previously published approaches, CVnCoV is exclusively composed of naturally occurring nucleotides. Immunisation with CVnCoV induced strong humoral responses with high titres of virus-neutralising antibodies and robust T-cell responses. CVnCoV vaccination protected hamsters from challenge with wild-type SARS-CoV-2, demonstrated by the absence of viral replication in the lungs. Hamsters vaccinated with a suboptimal dose of CVnCoV leading to breakthrough viral replication exhibited no evidence of vaccine-enhanced disease. Overall, data presented here provide evidence that CVnCoV represents a potent and safe vaccine candidate against SARS-CoV-2.
Identifiants
pubmed: 33863911
doi: 10.1038/s41541-021-00311-w
pii: 10.1038/s41541-021-00311-w
pmc: PMC8052455
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57Références
Hoerr, I., Obst, R., Rammensee, H. G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1–7 (2000).
pubmed: 10602021
doi: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#
Fotin-Mleczek, M. et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14, 428–439 (2012).
pubmed: 22262664
doi: 10.1002/jgm.2605
Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34, 1–15 (2011).
pubmed: 21150709
doi: 10.1097/CJI.0b013e3181f7dbe8
Kubler, H. et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J. Immunother. Cancer 3, 26 (2015).
pubmed: 26082837
pmcid: 4468959
doi: 10.1186/s40425-015-0068-y
Stitz, L. et al. A thermostable messenger RNA based vaccine against rabies. PLoS Negl. Trop. Dis. 11, e0006108 (2017).
pubmed: 29216187
pmcid: 5737050
doi: 10.1371/journal.pntd.0006108
Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).
pubmed: 29263884
pmcid: 5648897
doi: 10.1038/s41541-017-0032-6
Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).
pubmed: 27336830
pmcid: 4918980
doi: 10.1371/journal.pntd.0004746
Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210–1216 (2012).
pubmed: 23159882
doi: 10.1038/nbt.2436
Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).
pubmed: 28754494
doi: 10.1016/S0140-6736(17)31665-3
Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front Immunol. 9, 1963 (2018).
pubmed: 30283434
pmcid: 6156540
doi: 10.3389/fimmu.2018.01963
Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39, 1310–1318 (2021).
pubmed: 33487468
pmcid: 7825876
doi: 10.1016/j.vaccine.2020.12.070
Corbett, K. S. et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med 383, 1544–1555 (2020).
pubmed: 32722908
doi: 10.1056/NEJMoa2024671
Vogel, A. B. et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv 2020.09.08.280818 (2020).
Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438 (2020).
pubmed: 32991794
doi: 10.1056/NEJMoa2028436
Kalnin, K. V. et al. Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates. bioRxiv 2020.10.14.337535 (2020).
Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020).
pubmed: 32785213
doi: 10.1038/s41586-020-2639-4
Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).
pubmed: 14647384
pmcid: 7095016
doi: 10.1038/nature02145
Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
pubmed: 32015507
pmcid: 7095418
doi: 10.1038/s41586-020-2012-7
Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020).
pubmed: 32094589
doi: 10.1038/s41564-020-0688-y
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Huang, Y., Yang, C., Xu, X. F., Xu, W. & Liu, S. W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharm. Sin. 41, 1141–1149 (2020).
doi: 10.1038/s41401-020-0485-4
Chi, X. et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat. Commun. 11, 4528 (2020).
pubmed: 32913273
pmcid: 7483421
doi: 10.1038/s41467-020-18387-8
Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727–11734 (2020).
pubmed: 32376634
doi: 10.1073/pnas.2003138117
pmcid: 7260975
Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348–E7357 (2017).
pubmed: 28807998
doi: 10.1073/pnas.1707304114
pmcid: 5584442
Kirchdoerfer, R. N. et al. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 8, 15701 (2018).
pubmed: 30356097
pmcid: 6200764
doi: 10.1038/s41598-018-34171-7
Munoz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509–515 (2020).
pubmed: 32967005
doi: 10.1038/s41586-020-2787-6
pmcid: 8136862
Kremsner, P. et al. Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. medRxiv 2020.11.09.20228551 (2020).
Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779–784.e5 (2020).
pubmed: 32362314
pmcid: 7194065
doi: 10.1016/j.molcel.2020.04.022
Salazar, E. et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRxiv (2020).
Horner, C. et al. A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc Natl Acad Sci USA (2020).
Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464–1468 (2020).
pubmed: 33184236
pmcid: 7775736
doi: 10.1126/science.abe8499
Younes, S., Younes, N., Shurrab, F. & Nasrallah, G. K. Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review. Rev. Med. Virol. e2196 https://doi.org/10.1002/rmv.2196 (2020). Epub ahead of print.
Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428–2446 (2020).
pubmed: 32215622
doi: 10.1093/cid/ciaa644
Boudewijns, R. et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat. Commun. 11, 5838 (2020).
pubmed: 33203860
pmcid: 7672082
doi: 10.1038/s41467-020-19684-y
Osterrieder, N. et al. Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. Viruses 12, 779 (2020).
pmcid: 7412213
doi: 10.3390/v12070779
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).
pubmed: 32571934
doi: 10.1073/pnas.2009799117
pmcid: 7368255
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
pubmed: 32756549
pmcid: 7581537
doi: 10.1038/s41586-020-2622-0
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
pubmed: 32155444
pmcid: 7102599
doi: 10.1016/j.cell.2020.02.058
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
pubmed: 32075877
pmcid: 7164637
doi: 10.1126/science.abb2507
Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).
pubmed: 32698192
doi: 10.1038/s41586-020-2571-7
Schmidt, M. E. & Varga, S. M. The CD8 T cell response to respiratory virus infections. Front Immunol. 9, 678 (2018).
pubmed: 29686673
pmcid: 5900024
doi: 10.3389/fimmu.2018.00678
Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med 19, 1305–1312 (2013).
pubmed: 24056771
doi: 10.1038/nm.3350
Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. 88, 11034–11044 (2014).
pubmed: 25056892
pmcid: 4178831
doi: 10.1128/JVI.01505-14
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2020).
pubmed: 33276369
doi: 10.1038/s41586-020-03041-6
pmcid: 7906955
van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv (2020).
Smatti, M. K., Al Thani, A. A. & Yassine, H. M. Viral-induced enhanced disease illness. Front Microbiol. 9, 2991 (2018).
pubmed: 30568643
pmcid: 6290032
doi: 10.3389/fmicb.2018.02991
Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945–946 (2020).
pubmed: 32385100
doi: 10.1126/science.abb8923
Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185–1191 (2020).
pubmed: 32908214
doi: 10.1038/s41564-020-00789-5
Olsen, C. W., Corapi, W. V., Ngichabe, C. K., Baines, J. D. & Scott, F. W. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J. Virol. 66, 956–965 (1992).
pubmed: 1309922
pmcid: 240797
doi: 10.1128/jvi.66.2.956-965.1992
Fulginiti, V. A., Eller, J. J., Downie, A. W. & Kempe, C. H. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202, 1075–1080 (1967).
pubmed: 6072745
doi: 10.1001/jama.1967.03130250057008
Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
pubmed: 4305198
doi: 10.1093/oxfordjournals.aje.a120955
Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L. & Tan, W. S. Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus. Front Microbiol. 10, 1781 (2019).
pubmed: 31428074
pmcid: 6688523
doi: 10.3389/fmicb.2019.01781
Song, Z. et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 11, 59 (2019).
pmcid: 6357155
doi: 10.3390/v11010059
Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020).
pubmed: 32731257
pmcid: 7581548
doi: 10.1038/s41586-020-2607-z
Guebre-Xabier, M. et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. bioRxiv 2020.08.18.256578 (2020).